Cited 0 times in
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 원종윤 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 한대훈 | - |
dc.contributor.author | 한소정 | - |
dc.date.accessioned | 2021-01-19T08:06:04Z | - |
dc.date.available | 2021-01-19T08:06:04Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/181465 | - |
dc.description.abstract | Backgrounds and aims: Molecular-targeted agents are acceptable standards to treat advanced-stage hepatocellular carcinoma (HCC), however, their therapeutic benefit, ie, sorafenib, was significantly offset in case of major vessel invasion. Liver-directed concurrent chemo-radiotherapy (LD-CCRT) provided favorable outcomes in terms of survivals and tumor shrinkage, so, we appraised its long-term therapeutic efficacy. Patients and methods: Advanced HCC patients with portal vein invasion (main trunk or the 1st order branch) were enrolled. During a 5-week radiotherapy course, concurrent hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and leucovorin was administered through an implanted port on the first and last 5 days. Four weeks after LD-CCRT, a maintenance HAIC using 5-fluorouracil and cisplatin was administered every 4 weeks. Results: Among 152 patients, the objective response rates as the best response by modified Response Evaluation Criteria In Solid Tumors were 48.0% after LD-CCRT and 55.3% during subsequent HAIC maintenance. After LD-CCRT, biological responses in alpha-fetoprotein and protein induced by the absence of vitamin K or antagonist-II levels were achieved in 46.2% and 52.6%, respectively. Sixteen patients (10.5%) underwent curative resection or liver transplantation after down-staging. Median overall survival and progression-free survival were 13.5 and 6.9 months, respectively. Conclusion: LD-CCRT followed by maintenance HAIC yielded favorable survival outcomes in advanced HCC patients with major portal vein invasion. Through initial tumor reduction, LD-CCRT induced down-staging with subsequent curative treatment feasible in 10.5% of patients, resulting in long-term survival. Further prospective trials are warranted to confirm these results. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Dove Press | - |
dc.relation.isPartOf | JOURNAL OF HEPATOCELLULAR CARCINOMA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sojung Han | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Jong Yun Won | - |
dc.contributor.googleauthor | Dai Hoon Han | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.identifier.doi | 10.2147/JHC.S276528 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02443 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A04273 | - |
dc.contributor.localId | A05438 | - |
dc.relation.journalcode | J03970 | - |
dc.identifier.eissn | 2253-5969 | - |
dc.identifier.pmid | 33365287 | - |
dc.subject.keyword | concurrent chemoradiotherapy | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | portal vein invasion | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | response | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 성진실 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 원종윤 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.contributor.affiliatedAuthor | 한대훈 | - |
dc.contributor.affiliatedAuthor | 한소정 | - |
dc.citation.volume | 7 | - |
dc.citation.startPage | 403 | - |
dc.citation.endPage | 412 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEPATOCELLULAR CARCINOMA, Vol.7 : 403-412, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.